Related Experiment Video

Updated: Sep 6, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.8K

Socioeconomic and Racial Disparity in Chimeric antigen receptor T cell (CART)Therapy Access

Brandon Blue1

  • 1Assistant Member, Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL USA.

Transplantation and Cellular Therapy
|July 2, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K
Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

1.1K

Related Experiment Videos

Last Updated: Sep 6, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.8K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K
Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

1.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

Articles linked to this work by shared authors, journal, and citation graph.

Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.

Bone marrow transplantation·2026

Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease.

Frontiers in oncology·2025

Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma.

Haematologica·2025

Hydrated cable bacteria exhibit protonic conductivity over long distances.

Proceedings of the National Academy of Sciences of the United States of America·2025

Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes.

Blood·2024

Real-World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: A Target Trial Emulation.

Transplantation and cellular therapy·2026

Child Opportunity Index and Survival After Pediatric Hematopoietic Cell Transplantation for Acute Leukemia.

Transplantation and cellular therapy·2026

Trends and Predictors of Hematopoietic Cell Transplant Utilization for HIV-lymphoma in California, 1991-2016.

Transplantation and cellular therapy·2026

Risk Factors for Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation Using Rabbit Anti-thymocyte Globulin or Porcine Anti-human T Lymphocyte Immunoglobulin in the Letermovir Era.

Transplantation and cellular therapy·2026

Early prophylactic rituximab reduces EBV infection and PTLD in high-risk patients receiving allogeneic hematopoietic stem cell transplantation.

Transplantation and cellular therapy·2026

Early Broad-Spectrum Antibiotic Exposure Is Associated with Increased Relapse after Myeloablative TBI-Based Allogeneic Hematopoietic Cell Transplantation.

Transplantation and cellular therapy·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us